Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype?

Targa Dias Anastacio H, Matosin N, Ooi L. · 2022

Read Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype? by Targa Dias Anastacio H, Matosin N, Ooi L. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9217953.txt.

Introduction

Targa Dias Anastacio and co-authors examine neuronal hyperexcitability in Alzheimer's disease and its drivers. Brain overactivity appears early in the disease, in cortex and hippocampus. Later stages instead show reduced activity. Finding the drivers could yield new drug targets.

The review sums up proof from patients, animal models, and cell models. Suspected drivers include abnormal calcium and glutamate levels in cells. Amyloid beta and tau pathology also play a part. Genetic risk factors like APOE and faulty inhibitory neurons and glia add to the picture. The authors argue the trait could serve as an early marker of cognitive decline. They list targets for future treatment work.

Catalog record

CREATORTarga Dias Anastacio H, Matosin N, Ooi L.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE94 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9217953

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype? By Helena Targa Dias Anastacio, Natalie Matosin, Lezanne Ooi Published in: Translational Psychiatry DOI: 10.1038/s41398-022-02024-7 ABSTRACT Alzheimer’s disease (AD) is a progressive neurodegenerative disorder leading to loss of cognitive abilities and ultimately, death. With no cure available, limited treatments mostly focus on symptom management. Identifying early changes in the disease course may provide new therapeutic targets to halt or reverse disease progression. Clinical studies have shown that cortical and hippocampal hyperactivity are a feature shared by patients in the early stages of disease, progressing to hypoactivity during later stages of neurodegeneration. The exact mechanisms causing neuronal excitability changes are not fully characterized; however, animal and cell models have provided insights into some of the factors involved in this phenotype. In this review, we summarize the evidence for neuronal excitability changes over the course of AD onset and progression and the molecular mechanisms underpinning these differences. Specifically, we discuss contributors to aberrant neuronal excitability, including abnormal levels of intracellular Ca2+ and glutamate, pathological amyloid β (Aβ) and tau, genetic risk factors, including APOE, and impaired inhibitory interneuron and glial function. In light of recent research indicating hyperexcitability could be a predictive marker of cognitive dysfunction, we further argue that the hyperexcitability phenotype could be leveraged to improve the diagnosis and treatment of AD, and present potential targets for future AD treatment development. ALZHEIMER’S DISEASE AND NEURONAL HYPEREXCITABILITY It is estimated that approximately 50 million people worldwide suffer from dementia [1]. Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 60–80% of all cases [2]. AD causes a progressive decline in cognitive function and eventually leads to death. Amyloid plaque deposition and neurofibrillary tangles (NFT) in the brain are the main pathological hallmarks of this disease. Amyloid plaques are comprised of insoluble Aβ peptides that accumulate in the extracellular space [3], while NFTs are intraneuronal aggregates containing hyperphosphorylated and misfolded tau [4]. AD can be caused by mutations in genes involved in the processing of Aβ, including APP, PSEN1, and PSEN2 [5]. However, familial inherited genetic cases of the disease (familial AD, FAD) represent only around 2% of total cases [6]. The majority of cases are sporadic AD or late-onset Alzheimer’s disease (LOAD), where the disease is driven by a combination of genetic and other risk factors. One of the major genetic risk factors for LOAD is the APOE4 allele. There are three different alleles for the APOE gene: ε2, ε3, and ε4. The allele ε3 is the most common in the general population, and while ε4 increases the risk for AD, ε2 is protective against the disease [7]. Despite decades of research into the genetic basis and pathological mechanisms of AD, there is no treatment available to halt or reverse its progression, leading to an urgency for the development of new treatment options. Neuronal hyperexcitability can be detected, in a non-invasive manner, before the onset of dementia [8, 9]. Therefore, potentially, this phenotype could be harnessed to identify individuals at risk and start treatments before degeneration progresses too far. Hyperexcitability can be defined as the increased likelihood that a neuron will be activated by a certain stimulus. In patients, neuronal hyperexcitability has been observed via enhanced brain activity when individuals perform a memory-encoding task [8–10]. In preclinical animal and cell models of AD, neurons show a higher frequency of action potential firing, as well as a lower threshold for firing [11–15]. Importantly, activity recordings at the level of single neurons, neuronal networks or even entire brain regions consistently show hyperexcitability in the early stages of AD (summarized in Table 1). This evidence comes from laboratory models of AD, as well as living patients, showcasing the potential of neuronal excitability changes as a biomarker for early detection of AD. Beyond that, the molecular mechanisms driving neuronal hyperexcitability are also potential targets for therapeutic intervention, which holds promise for halting or reversing AD. Recent data from mouse studies show that reversing abnormal neuronal excitability in brain regions affected early in the process of Aβ deposition not only reduces Aβ load in the same brain region but also prevents the spread of Aβ pathology to other areas of the brain [16]. Since Aβ accumulation is thought to contribute to memory deficits and neurodegeneration, these results provide initial evidence that reducing neuronal excitability could provide a potential therapeutic avenue for AD. However, the exact mechanisms leading to hyperexcitability are not yet fully understood and several questions need to be answered before we can effectively advance with treatment development. In this review, we summarize the current evidence available on neuronal excitability changes in AD, highlight the gaps in the field and identify pathways forward for future research.Table 1Evidence of neuronal hyperexcitability in patients, animal and cell models of Alzheimer’s disease.Study type/ Neuronal subtypeModel/Group of studyFunctional phenotypeMethodologyReferenceHuman studiesClinical study 16 non-demented APOE4 carriers (two APOE4/4 and 14 APOE3/4 subjects) Increased activity of parahippocampal, left hippocampal, parietal, temporal, and prefrontal regions of APOE4 carriersfMRI[18]14 non-demented APOE3/3 individualsClinical studyTen controls Increased hippocampal activity in MCI individuals compared to controlsfMRI[9]Nine mild MCI patientsDecreased hippocampal and entorhinal activity in AD patients compared to controlsTen AD patientsClinical study 90 controlsIncreased activity of the hippocampus, frontal, and temporal lobes of asymptomatic offspring of AD patientsfMRI[17]95 asymptomatic offspring of AD patientsClinical study15 controls Increased hippocampal activity in less impaired MCI subjects compared to controlsfMRI[8]15 less impaired MCI patientsDecreased hippocampal activity in more impaired MCI and mild AD subjects compared to control12 more impaired MCI patientsTen mild AD patientsClinical study19 controlsIncreased activity in the posterior hippocampal, parahippocampal and fusiform regions of MCI patients vs controlsfMRI[10]14 subjects with MCIBrain activity of AD patients was not significantly different from control11 patients with mild ADAnimal models Frontal, central, parietal, and occipital cortices of freely moving control and hAPP-J20 mice3–7 months non-transgenic mice (n = not specified) hAPP-J20 mice had frequent generalized cortical epileptiform discharges, which were absent in the controlEEG[26] 3–7 months mice expressing hAPP Swedish and Indiana mutations (n = 6 mice)Neurons of L2/3 frontal cortex of live control and APP23xPS45 mice6–10 months control mice (n = 10 mice; 564 neurons)Greater number of hyperactive (>4 transients/min) neurons in APPswe/PS1G384 miceCalcium imaging[11]6–10 months APPswe/PS1G384A mice (n = 20 mice; 564 neurons)L2/3 pyramidal neurons of cortical slices3–4.5 months non-transgenic mice (n = 10 mice; 6 neurons)Current injection induced action potential firing in APdE9 mice at subthreshold stimulus compared to controlsWhole-cell patch-clamp[15]Frontal cortex of freely moving control and APdE9 mice3–4.5 months mice harboring APPswe and PSEN1dE9 mutations25–65% of APdE9 mice had seizures, while none of the control animals exhibited this phenotypeEEG(n = 20 mice; nine neurons)Pyramidal neurons of lateral amygdala slices of APOE3 and APOE4 mice1 and 7 months human APOE3/E3 knock-in mice (n = 11 mice; 23 neurons) Reduced frequency of spontaneous excitatory postsynaptic currents in APOE4/E4 miceWhole-cell patch-clamp[32]1 and 7 months human APOE4/E4 knock-in mice (n = 12 mice; 28 neurons)CA1 pyramidal neurons of live control and APP23xPS45 mice1–2 months control mice (n = 6 mice; 693 neurons)Greater number of hyperactive (>20 transients/min) neurons in APPswe/PS1G384A miceCalcium imaging[28]1–2 months APPswe/PS1G384A mice (n = 7 mice; 818 neurons)6–7 months control mice (n = 5 mice; 312 neurons)6–7 months APPswe/PS1G384A mice (n = 5

Read the complete text